ABSTRACT
PURPOSE: To investigate the efficacy in best corrected visual acuity (BCVA) and central macularthickness after intravitreal bevacizumab injection in patients with macular edema. METHODS: Patients with macular edema due to branch retinal vein occlusion, central retinal vein occlusion, and diabetic retinopathy received intravitreal injection of bevacizumab (2.5 mg/0.1cc). Complete ophthalmic examinations including best corrected visual acuity and optical coherence tomography (OCT) were performed at baseline and follow-up visits for 6 months. RESULTS: In macular edema secondary to branch retinal vein occlusion, the mean BCVA improved from logMAR 0.62+/-0.30 at baseline to logMAR 0.43+/-0.37 at 1 month, 0.34+/-0.40 at 3 months and 0.38+/-0.37 at 6 months (p<0.05). The mean central macular thickness decreased from 451.2+/-118.9 micrometer at baseline to 280.3+/-124.6 micrometer at 1 month, 345.8+/-157.1 micrometer at 3 months and 312.9+/-174.4 micrometer at 6 months (p<0.05). In macular edema secondary to central retinal vein occlusion and diabetic retinopathy, visual improvement and macular thickness reduction were not statistically significant. CONCLUSIONS: Intravitreal bevacizumab injection appears to be more effective for macular edema due to branch retinal vein occlusion than macular edema secondary to central retinal vein occlusion and diabetic retinopathy.
Subject(s)
Humans , Antibodies, Monoclonal, Humanized , Diabetic Retinopathy , Follow-Up Studies , Intravitreal Injections , Macular Edema , Retinal Vein , Retinal Vein Occlusion , Tomography, Optical Coherence , Visual Acuity , BevacizumabABSTRACT
PURPOSE: To investigate the efficacy in best corrected visual acuity (BCVA) and central macularthickness after intravitreal bevacizumab injection in patients with macular edema. METHODS: Patients with macular edema due to branch retinal vein occlusion, central retinal vein occlusion, and diabetic retinopathy received intravitreal injection of bevacizumab (2.5 mg/0.1cc). Complete ophthalmic examinations including best corrected visual acuity and optical coherence tomography (OCT) were performed at baseline and follow-up visits for 6 months. RESULTS: In macular edema secondary to branch retinal vein occlusion, the mean BCVA improved from logMAR 0.62+/-0.30 at baseline to logMAR 0.43+/-0.37 at 1 month, 0.34+/-0.40 at 3 months and 0.38+/-0.37 at 6 months (p<0.05). The mean central macular thickness decreased from 451.2+/-118.9 micrometer at baseline to 280.3+/-124.6 micrometer at 1 month, 345.8+/-157.1 micrometer at 3 months and 312.9+/-174.4 micrometer at 6 months (p<0.05). In macular edema secondary to central retinal vein occlusion and diabetic retinopathy, visual improvement and macular thickness reduction were not statistically significant. CONCLUSIONS: Intravitreal bevacizumab injection appears to be more effective for macular edema due to branch retinal vein occlusion than macular edema secondary to central retinal vein occlusion and diabetic retinopathy.